LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Aeolus Pharmaceuticals, Inc. (OTCBB: AOLS - News) announced today that it has initiated the first of two expected pivotal studies of AEOL 10150 as a countermeasure to nuclear and radiological exposure. The study, led by Zeljko Vujaskovic, M.D. Ph.D. of Duke University, is designed to test the efficacy of AEOL 10150 as a treatment for damage to the lungs due to exposure to radiation and to determine the most effective dose, duration of delivery and the window of opportunity for treatment after exposure. Results from this study will lead to the final design of a pivotal study which is expected to begin early in 2009.
